Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Week in Review: Alphamab Closes $100 Million Series A for Oncology Candidates
Deals and Financings
Alphamab Oncology, a clinical-stage
Huadong Medicine (SHZ: 000963) closed its $222 million acquisition of Sinclair Pharma (L: SPH), a global aesthetics company headquartered in
Eli Lilly (NYSE: LLY) may sell China rights to a portfolio of older, off-patent antibiotics and CNS treatments in a deal that could bring between $200 and $300 million, industry sources said (see story). No specific drugs were named, and media reports did not disclose how many drugs might be included. Lilly wants to emphasize higher margin products, especially cancer drugs, and the company has been selling assets to raise cash that will be allocated to fund its new priorities.
Ascletis BioScience (HK: 1672) of Hangzhou acquired exclusive sales and marketing rights to Pegasys, a Shanghai Roche pegylated interferon used to treat hepatitis B and C (see story). Lindi Tan, PhD and CFO of Ascletis, told ChinaBio® Today that the agreement was a "transformational" event for Ascletis, because it gives the company's 145-member sales team two hepatitis products to market. In June, Ascletis received
HitGen, a
News and Analysis
WuXi Biologics (HK: 2269) has begun construction of a 1.6 million square foot global innovation center in
CASI Pharma (NSDQ: CASI), a US-China company, announced plans to build a global cGMP manufacturing facility in
Trials and Approvals
Gilead Sciences (NSDQ: GILD) announced approval to market Vemlidy® (tenofovir alafenamide), an oral treatment for hepatitis B, in
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China